Design-Zyme LLC
Lawrence, KS
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 4950 Research Park Way, Lawrence, KS 66047, USA
- Website
- design-zyme.com
- Founded
- 2024
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $2,999,999 |
Contract awards
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Bellbrook Labs LLC | Madison, WI | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Dotquant LLC | Shoreline, WA | — |
| Invvax, Inc. | Cypress, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Biological Mimetics, Inc. | Frederick, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| BPS Bioscience Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Design-Zyme LLC is a for-profit limited liability company registered in the System for Award Management (SAM.gov) since March 14, 2016, with registration valid through December 4, 2025. The company appears to be a biotechnology-focused small business that specializes in developing innovative enzyme and biosensor technologies for medical and scientific applications. Based on its federal award history, Design-Zyme LLC demonstrates expertise in creating advanced enzyme systems, biosensors, and vaccine-related biotechnological solutions.
The company's federal contract work is exemplified by a significant $2,999,999 SBIR Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID). This contract, competitively awarded under the small business set-aside program, focuses on developing a novel approach to Lyme disease vaccine technology. Specifically, the contract involves creating a covalently bound hyaluronic acid adjuvant for a multivalent Lyme disease vaccine, with a project completion date of September 29, 2027. The contract demonstrates Design-Zyme LLC's capability to engage in advanced biomedical research and development for federal civilian agencies, with a particular emphasis on innovative vaccine and immunological technologies.
Design-Zyme LLC has also secured multiple federal grants from the National Institute of General Medical Sciences, highlighting its research capabilities in enzyme and biosensor technologies. These grants include a project developing a cortisol sensing enzyme system utilizing dehydrogenases in biosensors (R43GM137652) and another exploring in vitro enzyme glycosylation as a platform for enzyme stabilization (R43GM137719). Both grants were relatively short-term project grants, with completion dates in 2021 and 2022 respectively. These awards underscore the company's expertise in advanced enzymatic research, biosensor development, and innovative approaches to enzyme modification and stabilization, positioning Design-Zyme LLC as a specialized biotechnology research entity with strong capabilities in creating advanced scientific platforms and solutions.
SBA capabilities narrative
Design-Zyme is involved in the production, modification, and testing of enzymes for use in health monitoring devices.
Quick answers
Is Design-Zyme LLC registered in SAM.gov?
Yes. Design-Zyme LLC's SAM.gov registration is active through January 16, 2027.
What is Design-Zyme LLC's CAGE code?
Design-Zyme LLC's CAGE code is 7KSG8, and its Unique Entity ID (UEI) is RM33XDX5RRG4.
How much has Design-Zyme LLC received in federal contracts?
Federal contracts obligated $2,999,999 to Design-Zyme LLC in fiscal years 2023 through 2027.
What is Design-Zyme LLC's most recent federal award?
Design-Zyme LLC's most recent federal contract award is Development of covalently bound hyaluronic acid as an adjuvant for multivalent lyme disease vaccine (75N93024C00016), from National Institute of Allergy and Infectious Diseases (NIH), on September 17, 2024.
On GovTribe
See Design-Zyme LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors